Tumors of female reproductive system

Опухоли женской репродуктивной системы

1994-40981999-8627

Publishing House ABV Press

310

10.17650/1994-4098-2009-0-3-4-276-287

MAMMOLOGY. TREATMENT

МАММОЛОГИЯ. ЛЕЧЕНИЕ

GENERAL PRINCIPLES OF DRUG TREATMENT FOR PRIMARY OPERABLE AND LOCALLY ADVANCED BREAST CANCER

ОБЩИЕ ПРИНЦИПЫ ЛЕКАРСТВЕННОГО ЛЕЧЕНИЯ ПЕРВИЧНО-ОПЕРАБЕЛЬНОГО И МЕСТНО-РАСПРОСТРАНЕННОГО РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ

Artamonova

E. V.

Артамонова

Е. В.

Russian Federation

N.N. Blokhin Russian Cancer Research Cancer, Russian Academy of Medical Sciences, MoscowГУ РОНЦ им. Н.Н. Блохина РАМН, Москва

10112009

3-4

29331009201410092014

2009

https://ojrs.abvpress.ru/ojrs/article/view/310

GENERAL PRINCIPLES OF DRUG TREATMENT FOR PRIMARY OPERABLE AND LOCALLY ADVANCED BREAST CANCER

1. Gianni L., Baselga J., Eiermann W. et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11:8715—21.

Gianni L., Baselga J., Eiermann W. et al. Feasibility and tolerability of sequential doxorubicin/paclitaxel followed by cyclophosphamide, methotrexate, and fluorouracil and its effects on tumor response as preoperative therapy. Clin Cancer Res 2005;11:8715—21.

2. Fisher B., Bryant J., Wolmark N. et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672—85.

Fisher B., Bryant J., Wolmark N. et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998;16:2672—85.

3. Rastogi P., Anderson S.G., Bear H.D. et al. Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778—85.

Rastogi P., Anderson S.G., Bear H.D. et al. Preoperative chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008;26:778—85.

4. Von Minckwitz G., Kummel S., Vogel P. et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophos- phamide in early nonresponsive breast can- cer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100(8):521—3.

Von Minckwitz G., Kummel S., Vogel P. et al. Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophos- phamide in early nonresponsive breast can- cer: phase III randomized GeparTrio trial. J Natl Cancer Inst 2008;100(8):521—3.

5. Lazaridis G., Pentheroudakis G., Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol 2008;66(1):31—41.

Lazaridis G., Pentheroudakis G., Pavlidis N. Integrating trastuzumab in the neoadjuvant treatment of primary breast cancer: Accumulating evidence of efficacy, synergy and safety. Crit Rev Oncol Hematol 2008;66(1):31—41.

6. Gralow J.R., Burstein H.J., Wood W. et al. Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable dis- ease. J Clin Oncol 2008;26:814—9.

Gralow J.R., Burstein H.J., Wood W. et al. Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable dis- ease. J Clin Oncol 2008;26:814—9.

7. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the ran- domised trials. Lancet 2005;365:1687—717.

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15- year survival: an overview of the ran- domised trials. Lancet 2005;365:1687—717.

8. EBCTCG. New advances in the treat- ment of breast cancer. SABCS, San Antonio, TX, 2007.

EBCTCG. New advances in the treat- ment of breast cancer. SABCS, San Antonio, TX, 2007.

9. Coombes R.C., Kilburn L.S., Snowdon C.F. et al. Survival and safety of exemestane versus tamoxifen after 2—3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised con- trolled trial. Lancet 2007;369:559—70.

Coombes R.C., Kilburn L.S., Snowdon C.F. et al. Survival and safety of exemestane versus tamoxifen after 2—3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised con- trolled trial. Lancet 2007;369:559—70.

10.

10. Jakesz R., Kaumann M., Gnant M. et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and the ARNO 95 trial. Lancet 2005;366:455—62.

Jakesz R., Kaumann M., Gnant M. et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and the ARNO 95 trial. Lancet 2005;366:455—62.

11.

11. Jonat W., Gnant M., Boccardo F. et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in post- menopausal women with hormone-sensi- tive early-stage breast cancer: a meta- analysis. Lancet Oncol 2006;7:991—6.

Jonat W., Gnant M., Boccardo F. et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in post- menopausal women with hormone-sensi- tive early-stage breast cancer: a meta- analysis. Lancet Oncol 2006;7:991—6.

12.

12. Forbes J.F., Cuzick J., Buzdar A.U. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45—53.

Forbes J.F., Cuzick J., Buzdar A.U. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9:45—53.

13.

13. Buzdar A.U. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer. J Clin Oncol 2007;25:486—92.

Buzdar A.U. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer. J Clin Oncol 2007;25:486—92.

14.

14. Goss P.E., Ingle J.N., Martino S. et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updat- ed findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262—71.

Goss P.E., Ingle J.N., Martino S. et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updat- ed findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262—71.

15.

15. Mamounas E., Jeong J.-H., Wickerham L. et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 2006;100(Suppl 1):22. Abstr 49.

Mamounas E., Jeong J.-H., Wickerham L. et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 2006;100(Suppl 1):22. Abstr 49.

16.

16. Piccart-Gebhart M.J., Procter M., Leyland-Jones H. et al. Trastuzumab after adjuvant chemotherapy in Her-2- positive breast cancer. N Engl J Med 2005;353:1659—72.

Piccart-Gebhart M.J., Procter M., Leyland-Jones H. et al. Trastuzumab after adjuvant chemotherapy in Her-2- positive breast cancer. N Engl J Med 2005;353:1659—72.

17.

17. Perez E.A., Romond E.H., Suman V.J. et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/with-out trastuzumab in patients with Her-2- positive breast cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25(18):512.

Perez E.A., Romond E.H., Suman V.J. et al. Updated results of the combined analysis of NCCTG N9831 and NSABP B-31 adjuvant chemotherapy with/with-out trastuzumab in patients with Her-2- positive breast cancer. ASCO Annual Meeting Proceedings (Post-Meeting Edition). J Clin Oncol 2007;25(18):512.

18.

18. Slamon D., Eiermann W., Robert N. et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of Her-2-positive early breast cancer patients: second interim efficacy analysis. SABCS, 2006. Abstr 209.

Slamon D., Eiermann W., Robert N. et al. Phase III trial comparing AC-T with AC-TH and with TCH in the adjuvant treatment of Her-2-positive early breast cancer patients: second interim efficacy analysis. SABCS, 2006. Abstr 209.

19.

19. Joensuu H., Kellokumpu-Lehtinen P.-L., Bono P. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809—20.

Joensuu H., Kellokumpu-Lehtinen P.-L., Bono P. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006;354:809—20.

20.

20. Jones S., Holmes F., O'Shaughnessy J. et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophos- phamide and is well-tolerated in women 65 or older. Breast Cancer Res Treat 2007;106(Suppl 1):5. Abstr 12.

Jones S., Holmes F., O'Shaughnessy J. et al. Extended follow-up and analysis by age of the US Oncology Adjuvant trial 9735: docetaxel/cyclophosphamide is associated with an overall survival benefit compared to doxorubicin/cyclophos- phamide and is well-tolerated in women 65 or older. Breast Cancer Res Treat 2007;106(Suppl 1):5. Abstr 12.

21.

21. Martin M., Pienkowsky T., Mackey J. et al. Adjuvant docetaxel for node-posi- tive breast cancer. N Engl J Med 2005;352(22):2302—12.

Martin M., Pienkowsky T., Mackey J. et al. Adjuvant docetaxel for node-posi- tive breast cancer. N Engl J Med 2005;352(22):2302—12.

22.

22. Martin M., Lluch A., SeguТ M.A. et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte- colony stimulating factor to the TAC regi- men. Ann Oncol 2006;17(8):1205—12.

Martin M., Lluch A., SeguТ M.A. et al. Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte- colony stimulating factor to the TAC regi- men. Ann Oncol 2006;17(8):1205—12.

23.

23. Hayes D.F., Thor A.D., Dressler L.G. et al. Her-2 and response to paclitaxel in node-positive breast cancer. New Engl J Med 2007;357:1496-506.

Hayes D.F., Thor A.D., Dressler L.G. et al. Her-2 and response to paclitaxel in node-positive breast cancer. New Engl J Med 2007;357:1496-506.

24.

24. Roche H., Fumoleau P., Spielmann M. et al. Sequential adjuvant epirubicin- based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24(36):5664—71.

Roche H., Fumoleau P., Spielmann M. et al. Sequential adjuvant epirubicin- based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial. J Clin Oncol 2006;24(36):5664—71.